Literature DB >> 2129750

HLA-DP-positive T cells in patients with systemic lupus erythematosus.

Y Tokano1, T Hishikawa, T Hirose, I Sekigawa, H Hashimoto, K Okumura, S Hirose.   

Abstract

HLA-DP+ T cells in peripheral blood from 23 patients with systemic lupus erythematosus (SLE) were examined using two-colour flow cytometry analysis. A marked increase of HLA-DP+ T cells was observed in patients with SLE (20.5-98.7%; 59.8 +/- 20.8%) in comparison to normal subjects (1.3-20.6%; 11.1 +/- 7.2%), and the ratio of these cells greatly exceeded that of the HLA-DR+ T cells (6.5-49.1%; 21.5 +/- 12.7%). This high frequency of HLA-DP+ T cells in patients with active SLE decreased with prednisolone therapy. When the lymphocytes from normal subjects were stimulated with PHA in vitro, HLA-DP+ T cells increased from 1.8 to 59.2%. Therefore, it appears that the HLA-DP antigen expression on T cells is a practical marker for monitoring changes in the proportion of activated T cells in patients with SLE during the course of therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2129750     DOI: 10.3109/08916939009002976

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  3 in total

1.  Soluble Fas molecule in the serum of patients with systemic lupus erythematosus.

Authors:  Y Tokano; S Miyake; N Kayagaki; K Nozawa; S Morimoto; M Azuma; H Yagita; Y Takasaki; K Okumura; H Hashimoto
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

2.  Soluble CD4, CD8 in patients with polymyositis/dermatomyositis.

Authors:  Y Tokano; T Obara; H Hashimoto; K Okumura; S Hirose
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

3.  Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia.

Authors:  Y Amasaki; S Kobayashi; T Takeda; N Ogura; S Jodo; T Nakabayashi; A Tsutsumi; A Fujisaku; T Koike
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.